about
Biological characteristics and clinical outcome of triple negative primary breast cancer in older women - comparison with their younger counterparts.Long-term clinical outcome of oestrogen receptor-positive operable primary breast cancer in older women: a large series from a single centreSuccessful management of elderly breast cancer patients treated without radiotherapy.The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.Long-term (37 years) clinical outcome of older women with early operable primary breast cancer managed in a dedicated clinic.Radiotherapy as sole adjuvant treatment for older patients with low-risk breast cancer.Breast conservation in ductal carcinoma in situ (DCIS): what defines optimal margins?Redox protein expression predicts radiotherapeutic response in early-stage invasive breast cancer patients.A comparison of late cosmetic results following two different radiotherapy techniques for treating basal cell carcinoma.Vascular endothelial growth factor expression predicts outcome after primary radiotherapy for head and neck squamous cell cancer.Shortened irradiation scheme, continuous infusion of 5-fluorouracil and fractionation of mitomycin C in locally advanced anal carcinomas. Results of a phase II study of the European Organization for Research and Treatment of Cancer. Radiotherapy andA vision to optimise the management of primary breast cancer in older women.Should radiotherapy be omitted in women age 70 years or older with early breast cancer?A study of ductal versus non-ductal invasive breast carcinomas in older women: long-term clinical outcome and comparison with their younger counterpartsOptimising the management of primary breast cancer in older women – A report of a multi-disciplinary study dayCare of the older woman with primary breast cancer: a sign of the times?Pathological features of primary breast cancer in the elderly based on needle core biopsies—A large series from a single centreBoost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer NetworkExpression of thioredoxin system and related peroxiredoxin proteins is associated with clinical outcome in radiotherapy treated early stage breast cancerRadiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trialThe prognostic significance of lymphovascular invasion in invasive breast carcinomaSurvival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990–1999Safe selection criteria for breast conservation without radical excision in primary operable invasive breast cancerLiver Kinase B1-A Potential Therapeutic Target in Hormone-Sensitive Breast Cancer in Older WomenEarly results of radiotherapy for advanced laryngeal cancer using three small fractions per dayProphylactic cranial irradiation for small-cell lung cancer: long-term resultsThe prediction of local or regional recurrence after simple mastectomy for operable breast cancerMaintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: a randomised, controlled trialRadiotherapy plus chemotherapy for head and neck cancerLocally advanced breast cancer: long-term results of a randomized trial comparing primary treatment with tamoxifen or radiotherapy in post-menopausal womenCarcinoma of the larynx and hypopharynx in the elderlyLeiomyosarcoma of the larynxPostoperative radiotherapy following mastectomy for high-risk breast cancer. A randomised trialIs local control necessarily an indicator of quality?Incidence of clinically significant lymphoedema as a complication following surgery for primary operable breast cancerBoost or notThe use of a commercial remote desktop program in the delineation of target volumes in radiotherapyMinimising carotid artery dose in the radiotherapy of early glottic cancerBiologic comparisons of partial breast irradiation schedules: In regard to Rosenstein et al. (Int J Radiat Oncol Biol Phys 2004;60:1391-1404)Cancer-information seeking
P50
Q33856732-4CA414A6-E15A-48B9-B021-ACD8F4851FEFQ35006855-74233764-B840-47EE-8673-B2BE25FF0529Q35843731-CAD4BE54-8B00-4D57-8EC9-4A017E72054DQ36514573-EF337FD8-A8BE-420F-8B23-260DEA7217FEQ37946357-CF254448-934A-41A8-A021-6C5929B4D8E6Q38024006-D6152387-4BB7-43B0-9037-4FCDFCBB0F66Q39045307-23DC6674-8B9B-4C13-9D6E-D3941A2AED92Q39785464-C22EB2F7-47D6-4129-81FB-9F4C764CCE6EQ42450112-2CCE348C-2F36-405A-AEC0-F9C50F1711DDQ43724359-BEC6EB3C-D0D2-47F2-9BB9-EA4FE7492840Q44264206-861824D1-AE16-424B-ABE7-27BEF82AFAF5Q44715439-480AE165-A03D-4D4B-86A1-0778D9C568E5Q45347696-7E1BEF52-9515-48C5-BEBA-110249853181Q58834538-E5D78385-AC06-461C-B9B1-5A63654D0D44Q58834557-A84729DB-8B3F-4763-BF87-795DD803360DQ58834567-EFBACCF9-786C-4E1A-8C3D-7DFFE2EA5E79Q58834568-BE5D850D-71A4-4A63-B242-362EB442A359Q58890551-2A0E8717-0557-4AC6-9964-AD4B0477A2DDQ62562263-0A6AF491-AB4A-418C-B1A5-6B1F66D0F5A1Q64018917-A3AE8008-A212-4ADE-B8E1-08B07FA80307Q64018926-B8A059D7-9A2E-470A-979E-DCA9AF87191BQ64018972-80A0C777-E85D-4134-8795-1B60BFBCC33FQ64019074-77FABE7D-846B-44F9-B6B0-7761401F4F7EQ64243712-AA3512D7-D24D-4786-A5C8-17FB5F234C45Q68695450-BCCDEEA5-3057-478F-8983-A788E080049AQ69366102-29437311-F498-4DA9-BEC0-1A30CD5D4701Q69907937-791FD895-7A06-4CFC-B93E-4E254D687F90Q70141997-FD28301C-AE29-427F-BF88-B926CE15F3BFQ70544622-05BDED2B-042F-4753-BF90-0E6F5F111D8CQ71627355-E888C8B0-FDF8-4BB9-B9E2-640CCE6DDA48Q71627375-252651B4-AA1C-47E4-9E10-DBA13C704FB3Q73147046-F75C6D7E-90B3-4BBD-8A97-149F7D327837Q74086879-074E17C0-730C-4684-8916-0B647214C63DQ76318785-328F119F-4C20-4052-A03E-FB61664E84D8Q79106671-6089E498-2EFF-4F46-90E6-70879582AD2FQ80723819-49334DC2-CE8D-4196-B5ED-E28F398EA534Q80888547-F2466F2E-D179-4263-9C48-A4D912C64794Q80977912-979116F8-462E-4978-8D33-0BEAFEE98FEBQ81814987-19584325-B0F6-4C84-A234-C57D7EC04203Q82760943-C7E7A05B-00A1-4D48-84B7-2B63883BC129
P50
description
researcher
@en
հետազոտող
@hy
name
David Morgan
@ast
David Morgan
@en
David Morgan
@es
David Morgan
@nl
type
label
David Morgan
@ast
David Morgan
@en
David Morgan
@es
David Morgan
@nl
prefLabel
David Morgan
@ast
David Morgan
@en
David Morgan
@es
David Morgan
@nl
P106
P1153
7403985361
P21
P31
P496
0000-0002-2291-1740